CAMBRIDGE, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced positive results from pooled data from two open-label, multicenter, randomized Phase III studies of ferumoxytol as an intravenous iron replacement therapeutic agent. The data are being presented at approximately 5:30 pm ET as a poster at the 8th American Transplant Congress in Toronto, Canada. The poster is available on the Company’s website at www.amagpharma.com.
